论文部分内容阅读
目的:观察普拉克索治疗原发性不宁腿综合征的疗效及安全性。方法:21例原发性不宁腿综合征患者应用普拉克索逐步加量治疗的方法,采用自身前后对照,以不宁腿严重程度量表(IRLS)、匹兹堡睡眠质量指数(PSQI)、汉密尔顿焦虑量表(HAMA)评估疗效。结果:治疗后21例患者的IRLS、PSQI、HAMA分值较治疗前均有不同程度的下降,差异有统计学意义(P<0.05)。结论:普拉克索治疗原发性不宁腿综合征疗效较好,不良反应相对轻微,对老年不宁腿综合征患者较适合。
Objective: To observe the efficacy and safety of pramipexole in the treatment of primary restless legs syndrome. Methods: Twenty-one patients with idiopathic restless legs syndrome were treated with pramipexole in a dose-dependent manner. Using IRLS, Pittsburgh Sleep Quality Index (PSQI), Hamiltonian Anxiety Scale (HAMA) assessment of efficacy. Results: The scores of IRLS, PSQI and HAMA in 21 patients decreased to some extent after treatment compared with before treatment, the difference was statistically significant (P <0.05). Conclusion: Pramipexole is effective in treating restless legs syndrome with relatively mild adverse reactions and is suitable for elderly patients with restless legs syndrome.